Rampart Bioscience

About Rampart Bioscience

Rampart Bioscience is a biotech startup that is pioneering a new class of gene medicines for patients suffering from genetically driven diseases. The company operates in the gene therapy market, focusing on the development of non-viral DNA delivery systems. This innovative approach aims to overcome the limitations of current gene therapies, offering higher standards for potency, durability, redosability, and safety.

Rampart Bioscience's business model revolves around integrating capabilities from various scientific disciplines such as gene delivery, protein sciences, and clinical translation. The company's goal is to provide safe, long-lasting treatments for a wide range of diseases. Their proprietary development and delivery platforms enable them to create optimized therapeutics in a redosable, non-viral format.

The company's primary revenue stream comes from the development and commercialization of these gene therapies. They have already made progress in creating a new mechanism for treating an inherited metabolic disorder and are advancing with other high-need applications in genetic disease.

Rampart Bioscience's team comprises talented leaders from various fields, all committed to transcending boundaries and forging a brighter path for patients. The company prides itself on its patient-first culture, authenticity, integrity, and personal freedom, and is driven by the goal of making a positive impact on the world.